Arcus Biosciences (RCUS) shareholder files notice to sell 22000 shares

Rhea-AI Filing Summary

Arcus Biosciences, Inc. had a shareholder file a notice to sell 22000 shares of common stock through E*TRADE on the NYSE, with an aggregate market value of 481800. Shares outstanding were 122856086; this is a baseline figure, not the amount being sold.

The shares to be sold were acquired on 12/15/2025 through vesting of restricted stock granted on 03/08/2022, 01/23/2023, 01/23/2024 and 01/23/2025 as payment for services rendered. The same seller previously disposed of 12500, 37792 and 50291 shares of common stock on 10/06/2025, 10/08/2025 and 11/07/2025, respectively, for gross proceeds of 181800.77, 568610.88 and 954066.32, and represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 3005	22000	481800	122856086	12/16/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	12/15/2025	Vesting of restricted stock granted 3/8/2022	Arcus Biosciences, Inc.			7812	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2023	Arcus Biosciences, Inc.			11450	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2024	Arcus Biosciences, Inc.			10000	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2025	Arcus Biosciences, Inc.			12500	12/15/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jennifer Jarrett 3928 Point Eden Way Hayward CA 94545	COMMON STOCK	10/06/2025	12500	181800.77
Jennifer Jarrett 3928 Point Eden Way Hayward CA 94545	COMMON STOCK	10/08/2025	37792	568610.88
Jennifer Jarrett 3928 Point Eden Way Hayward CA 94545	COMMON STOCK	11/07/2025	50291	954066.32

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What stock sale does the RCUS filing describe?

The notice describes a planned sale of 22000 shares of Arcus Biosciences, Inc. common stock through E*TRADE on the NYSE, with an aggregate market value of 481800.

Who is selling Arcus Biosciences (RCUS) shares in this notice?

The securities are to be sold for the account of Jennifer Jarrett, listed with an address at 3928 Point Eden Way, Hayward CA 94545, as the person for whose account the common stock will be sold.

How were the RCUS shares being sold acquired?

The common shares to be sold were acquired on 12/15/2025 through vesting of restricted stock granted on 03/08/2022, 01/23/2023, 01/23/2024 and 01/23/2025, with amounts including 7812, 11450, 10000 and 12500 shares, as consideration for services rendered.

What Arcus Biosciences (RCUS) share sales occurred in the past 3 months?

In the past 3 months, the seller disposed of 12500 shares of common stock on 10/06/2025 for gross proceeds of 181800.77, 37792 shares on 10/08/2025 for 568610.88, and 50291 shares on 11/07/2025 for 954066.32.

How many Arcus Biosciences (RCUS) shares are outstanding in this filing?

The filing reports that 122856086 shares of Arcus Biosciences, Inc. common stock were outstanding, which serves as a baseline figure alongside the planned sale of 22000 shares.

What representation does the seller make about Arcus Biosciences (RCUS)?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information regarding the current or prospective operations of Arcus Biosciences, Inc. that has not been publicly disclosed.